These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17026517)

  • 21. Decreased immunoreactivity of CD99 is an independent predictor of regional lymph node metastases in pulmonary carcinoid tumors.
    Pelosi G; Leon ME; Veronesi G; Spaggiari L; Pasini F; Viale G
    J Thorac Oncol; 2006 Jun; 1(5):468-77. PubMed ID: 17409901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases.
    Zhang PJ; Barcos M; Stewart CC; Block AW; Sait S; Brooks JJ
    Mod Pathol; 2000 Apr; 13(4):452-8. PubMed ID: 10786814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Lung metastases in a primitive neuroectodermal tumor].
    Todea D; Rosca L
    Pneumologia; 2007; 56(1):35-7. PubMed ID: 17491207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD163 is not a sensitive marker for identification of atypical fibroxanthoma.
    Beer TW
    J Cutan Pathol; 2012 Jan; 39(1):29-32. PubMed ID: 22211334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical fibroxanthoma presenting immunoreactivity against CD10 and CD99.
    Nakamura Y; Abe Y; Ichimiya M; Muto M
    J Dermatol; 2010 Apr; 37(4):387-9. PubMed ID: 20507414
    [No Abstract]   [Full Text] [Related]  

  • 26. Atypical fibroxanthoma with pseudoangiomatous features: a histological and immunohistochemical mimic of cutaneous angiosarcoma.
    Thum C; Husain EA; Mulholland K; Hornick JL; Brenn T
    Ann Diagn Pathol; 2013 Dec; 17(6):502-7. PubMed ID: 24080496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical staining of CD10 in atypical fibroxanthomas.
    Hultgren TL; DiMaio DJ
    J Cutan Pathol; 2007 May; 34(5):415-9. PubMed ID: 17448198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primitive neuroectodermal tumor of the pancreas. An extremely rare tumor. Case report and review of the literature.
    Bülchmann G; Schuster T; Haas RJ; Joppich I
    Klin Padiatr; 2000; 212(4):185-8. PubMed ID: 10994548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma.
    de Feraudy S; Mar N; McCalmont TH
    Am J Surg Pathol; 2008 Aug; 32(8):1111-22. PubMed ID: 18545147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD99 (p30/32MIC2) immunoreactivity in the diagnosis of leukemia cutis.
    Dorfman DM; Kraus M; Perez-Atayde AR; Barnhill RL; Pinkus GS; Granter SR
    Mod Pathol; 1997 Apr; 10(4):283-8. PubMed ID: 9110288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathologic study of retinoblastoma including MIB-1, p53, and CD99 immunohistochemistry.
    Schwimer CJ; Prayson RA
    Ann Diagn Pathol; 2001 Jun; 5(3):148-54. PubMed ID: 11436168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of CD99/MIC2 expression of human AHTO-7 osteoblasts by carcinoma cell line-conditioned media.
    Hamilton D; Mallinger R; Millesi H; Engel A; Baumgartner G; Raderer M
    Anticancer Res; 2001; 21(6A):3909-13. PubMed ID: 11911268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD99 expression in hepatocellular carcinoma: an immunohistochemical study in the fibrolamellar and common variant of the tumour.
    Vasdev N; Nayak NC
    Indian J Pathol Microbiol; 2003 Oct; 46(4):625-9. PubMed ID: 15025359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD99 - much ado about nothing?
    Pozdnyakova O; Mahalingam M
    J Cutan Pathol; 2008 Jan; 35(1):86-7. PubMed ID: 18096002
    [No Abstract]   [Full Text] [Related]  

  • 35. CD99 correlates with low cyclin D1, high topoisomerase 2 status and triple negative molecular phenotype but is prognostically irrelevant in breast carcinoma.
    Czapiewski P; Wełnicka-Jaśkiewicz M; Seroczyńska B; Skokowski J; Sejda A; Szade J; Wiewiora C; Biernat W; Żaczek A
    Pol J Pathol; 2015 Sep; 66(3):269-75. PubMed ID: 26619106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of CD99 in pleomorphic carcinomas of the lung.
    Yoo SH; Han J; Kim TJ; Chung DH
    J Korean Med Sci; 2005 Feb; 20(1):50-5. PubMed ID: 15716602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paranuclear dot-like immunostaining of CD99 in rhabdomyosarcoma.
    Huang SH; Wu SY; Chang KC
    Histopathology; 2013 Apr; 62(5):814-6. PubMed ID: 23347163
    [No Abstract]   [Full Text] [Related]  

  • 38. Primary Ewing sarcoma of lumbar spine with massive intraspinal extension.
    Song X; Choi J; Rao C; Nallu S; Nicastri AD
    Pediatr Neurol; 2008 Jan; 38(1):58-60. PubMed ID: 18054697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoreactivity of CD99 in stomach cancer.
    Jung KC; Park WS; Bae YM; Hahn JH; Hahn K; Lee H; Lee HW; Koo HJ; Shin HJ; Shin HS; Park YE; Park SH
    J Korean Med Sci; 2002 Aug; 17(4):483-9. PubMed ID: 12172043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2.
    Fellinger EJ; Garin-Chesa P; Triche TJ; Huvos AG; Rettig WJ
    Am J Pathol; 1991 Aug; 139(2):317-25. PubMed ID: 1867320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.